LONDON – After a second day of deliberation, the World Health Organization (WHO) held off declaring that the novel coronavirus infection raging in Wuhan is an international health emergency, saying the low number of cases outside China means it is not time to escalate the response to this level.
LONDON – The World Health Organization held off declaring the novel coronavirus infection that has emerged in Wuhan, China, an international public health emergency, despite the fact that the number of confirmed cases tripled in the past week and the infection has spread to several other countries, including the U.S.
BEIJING – With promising phase II data in hand – and newly designated FDA orphan drug status – Suzhou, China-based Tennor Therapeutics Suzhou Co. Ltd. is gearing up to move into pivotal testing with TNP-2092 to treat prosthetic joint infections.
In response to the emergence of a new coronavirus seen recently in China, and now America, Novavax Inc. has initiated development of a vaccine candidate, the company told BioWorld. Company shares (NASDAQ:NVAX) climbed more than 71% Jan. 21, ending the day at $9.82.
Iterum Therapeutics plc found a lifeline in the securities purchase agreement it made with an investors group for a $51.9 million private placement. The company plans to use that money to develop sulopenem, a penem anti-infective compound with oral and I.V. formulations.
LONDON – Novo Repair has made new investments of $12 million, bringing the total invested by the specialist anti-infectives venture capital fund since it was set up two years ago to plug the gap in the early stage pipeline to $48 million.
While Novan Inc.’s phase III failure in treating molluscum contagiosum for patients ages 6 months and older battered its stock Friday, the company intends to take the positive data it gleaned to the FDA to discuss an NDA submission and a possible phase III trial for next year.
The stock at Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), after an especially rough Thursday, began healing a bit as investors took in the company’s decision to stop dosing and enrolling patients in its phase IIb Catalyst trials.
While Ebola virus disease in the U.S. is a rare occurrence, the FDA approval of Merck & Co. Inc.’s Ervebo, the agency’s first for preventing Ebola Zaire virus in people age 18 and older, will have a ripple effect across the world, especially Africa where its effects have been devastating for decades. Stockpiling such a vaccine is crucial to world safety as Ebola has long been a potential bioterrorism threat, especially after 9/11. In the world of theoretical biological warfare, where the virus could be weaponized and disseminated by aerosol, Ebola virus is considered the most dangerous, with fatality rates estimated between 25% to 90%.